-
公开(公告)号：US20100284906A1
公开(公告)日：2010-11-11
申请号：US12791418
申请日：2010-06-01
IPC分类号： A61K38/20 , A61K39/395 , A61K51/00 , A61K38/21 , A61P35/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
-
公开(公告)号：US20100015048A1
公开(公告)日：2010-01-21
申请号：US12553566
申请日：2009-09-03
IPC分类号： A61K51/00 , A61K38/20 , A61K38/21 , A61K39/395 , A61P37/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
-
公开(公告)号：US20100266497A1
公开(公告)日：2010-10-21
申请号：US12794823
申请日：2010-06-07
IPC分类号： A61K51/10 , A61K39/395 , A61P35/00 , C12N5/07 , C12N5/0781 , C12N5/0783 , A61K51/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。
-
公开(公告)号：US20080138333A1
公开(公告)日：2008-06-12
申请号：US11754902
申请日：2007-05-29
IPC分类号： A61K39/395 , A61P17/00 , A61P21/00 , A61P31/00 , A61P35/00 , A61K39/00 , A61K38/46 , A61K51/00 , A61K31/70 , A61K45/00 , A61K38/21
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
-
公开(公告)号：US07138103B2
公开(公告)日：2006-11-21
申请号：US10150654
申请日：2002-05-17
IPC分类号： A61K38/04 , A61K39/395 , A61K49/04 , A61K49/06 , A61K51/00
CPC分类号： A61K51/1048 , A61K47/665 , A61K47/6879 , A61K51/1063 , A61K2039/505 , B82Y5/00 , C07K5/0215 , C07K5/1016 , C07K5/1019 , C07K7/06 , C07K16/18 , C07K16/3007 , C07K16/3046 , C07K16/44 , C07K16/468 , C07K2317/12 , C07K2317/13 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2319/00
摘要： The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the targetable constructs and bi-specific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及可由具有特异性结合构建体的至少一个臂的双特异性抗体或抗体片段结合的可靶向构建体。 可靶向构建体包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向构建物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生可靶向构建体和双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
公开(公告)号：US20080166342A1
公开(公告)日：2008-07-10
申请号：US11867775
申请日：2007-10-05
IPC分类号： A61K39/395 , C07K16/28 , C07K19/00 , C12N9/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。
-
公开(公告)号：US07312318B2
公开(公告)日：2007-12-25
申请号：US10377122
申请日：2003-03-03
IPC分类号： C07K16/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。
-
公开(公告)号：US07919087B2
公开(公告)日：2011-04-05
申请号：US11754902
申请日：2007-05-29
IPC分类号： A61K39/395 , A61K39/40
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。
-
9.发明授权Chimeric, human and humanized anti-granulocyte antibodies and methods of use 有权嵌合，人和人源化抗粒细胞抗体及其使用方法公开(公告)号：US07541440B2
公开(公告)日：2009-06-02
申请号：US10672278
申请日：2003-09-29
CPC分类号： G01N33/57426 , A61K39/395 , A61K51/10 , A61K51/1027 , C07K16/2803 , C07K2317/24 , C07K2317/567 , C07K2319/00 , G01N2500/00 , A61K2300/00
摘要： The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.
摘要翻译： 本发明提供人源化，嵌合和人类MN3抗体，融合蛋白及其片段。 抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断粒细胞相关疾病和疾病如白血病。
-
公开(公告)号：US08613903B2
公开(公告)日：2013-12-24
申请号：US12556718
申请日：2009-09-10
CPC分类号： C07K16/2833 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2887 , C07K16/4241 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
摘要： Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.
-
-
-
-
-
-
-
-
-
搜索结果
314 条记录 (耗时 0.07 秒)
